Johnson & Johnson Secures FDA Label Expansion for Tremfya's 57% Joint Damage Reduction
JNJ•FDA approves Johnson & Johnson’s supplemental Biologics License Application for Tremfya, adding structural joint damage inhibition to its label for active psoriatic arthritis. Phase 3b APEX data showed a 57% reduction in radiographic progression from weeks 24 to 48 and met primary ACR20 and major secondary endpoints.
1. FDA Approves Label Expansion for Structural Damage
Johnson & Johnson received FDA approval to include evidence of inhibition of structural joint damage in Tremfya’s label for adults with active psoriatic arthritis, distinguishing it as the only IL-23 inhibitor with this outcome.
2. Phase 3b APEX Study Demonstrates Efficacy
In the 24-week double-blind APEX trial, Tremfya met its primary ACR20 endpoint and achieved a 57% reduction in radiographic progression from week 24 to 48 among placebo-switch patients, with no new safety signals.
3. Market Differentiation and Commercial Impact
This label update bolsters Tremfya’s positioning as a first-line treatment for bio-naïve PsA patients at risk of irreversible joint damage, potentially driving prescription growth and strengthening J&J’s competitive edge in immunology.
